Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression
暂无分享,去创建一个
R. Barker | J. Klein | N. Williams | D. Burn | T. Foltynie | N. Wood | Y. Ben-Shlomo | F. Baig | M. May | H. Morris | M. Hu | T. Barber | D. Grosset | M. Lawton | N. Bajaj | K. Grosset | N. Malek | D. Swallow | Thomas R. Barber | R. Barker
[1] B. Hayete,et al. Large-scale identification of clinical and genetic predictors of Parkinson’s disease motor progression in newly-diagnosed patients: a longitudinal cohort study and validation , 2017, The Lancet Neurology.
[2] A. Dagher,et al. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression , 2017, Brain : a journal of neurology.
[3] A. Lang,et al. Precision medicine for disease modification in Parkinson disease , 2017, Nature Reviews Neurology.
[4] R. Barker,et al. Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease , 2016, Parkinsonism & related disorders.
[5] R. Barker,et al. Tracking Parkinson’s: Study Design and Baseline Patient Data , 2015, Journal of Parkinson's disease.
[6] Jean-François Gagnon,et al. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. , 2015, JAMA neurology.
[7] Y. Ben-Shlomo,et al. Parkinson’s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort , 2015, Journal of Parkinson's disease.
[8] Giuseppe Orefice,et al. The Heterogeneity of Early Parkinson’s Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients , 2013, PloS one.
[9] T. Robbins,et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[10] J. Nutt,et al. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. , 2012, British journal of clinical pharmacology.
[11] T. Feng,et al. Clinical heterogeneity in patients with early-stage Parkinson’s disease: a cluster analysis , 2011, Journal of Zhejiang University SCIENCE B.
[12] Werner Poewe,et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes , 2011, The Lancet Neurology.
[13] J. Marinus,et al. Clinical subtypes of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[14] C. Clarke,et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[15] W. Heiser,et al. The identification of Parkinson's disease subtypes using cluster analysis: A systematic review , 2010, Movement disorders : official journal of the Movement Disorder Society.
[16] T Revesz,et al. A clinico-pathological study of subtypes in Parkinson's disease. , 2009, Brain : a journal of neurology.
[17] D. Aarsland,et al. The association between motor subtypes and psychopathology in Parkinson's disease. , 2009, Parkinsonism & related disorders.
[18] J. Speelman,et al. Clinical heterogeneity in newly diagnosed Parkinson’s disease , 2008, Journal of Neurology.
[19] Nicholas H. G. Holford,et al. Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation , 2007, Pharmaceutical Research.
[20] J. Nutt,et al. Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[21] T. Robbins,et al. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[22] J. Nutt,et al. Modeling the Short- and Long-Duration Responses to Exogenous Levodopa and to Endogenous Levodopa Production in Parkinson's Disease , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[23] G. Polesello,et al. Clinical predictors in Parkinson's disease , 2002, Neurological Sciences.
[24] H. Sagar,et al. A data‐driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes , 1999, Movement disorders : official journal of the Movement Disorder Society.
[25] Donald Hedeker,et al. Application of random-efiects pattern-mixture models for miss-ing data in longitudinal studies , 1997 .
[26] Y Mizuno,et al. [Clinical subtypes of Parkinson's disease]. , 1993, No to shinkei = Brain and nerve.
[27] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[28] Y. Ben-Shlomo,et al. The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. , 2014, Parkinsonism & related disorders.
[29] M. Vidailhet. [Heterogeneity of Parkinson's disease]. , 2003, Bulletin de l'Academie nationale de medecine.